Physician profile
Jeri Lei Penkava
NPI 1134285430
$2,467.89
in general payments reported to CMS, 2019-2025
10 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Developmental - Behavioral Pediatrics provider received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $507 · 2021: $578 · 2022: $277 · 2023: $90.44 · 2024: $144 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $961.14 | 2019-2024 | |
| Tris Pharma INC | $444.43 | 2019-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $404.28 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $246.07 | 2020-2021 | |
| Adlon Therapeutics L.P. | $141.14 | 2020-2021 | |
| Corium, LLC | $106.11 | 2022-2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $65.01 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $62.89 | 2021-2022 | |
| Shire North American Group INC | $23.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeri Penkava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.